Navigation Links
Phase 3 data show viral cure rates achieved in a broad range of patients with genotype-1 hepatitis C taking investigational compound faldaprevir plus PegIFN/RBV
Date:11/2/2013

1% (PegIFN/RBV) of patients. Further, AEs leading to the discontinuation of faldaprevir occurred in 1% (120mg) and 3% (240mg) of patients.

In STARTVerso™3, AEs of at least moderate intensity in the 12- and 24-week faldaprevir arms included gastrointestinal side effects, which occurred in 20% (12-week), 17% (24-week) and 6% (PegIFN/RBV alone) of patients. Anemia occurred in 10% of patients in both faldaprevir arms (12- and 24-week) and 5% of patients taking (PegIFN/RBV alone). Rash, photosensitivity, and jaundice occurred in </= 5% of faldaprevir patients (12- or 24-week arms). Further, AEs leading to the discontinuation of faldaprevir occurred in 7% (12-week) and 8% (24-week) of patients. In STARTVerso™4 to date, nausea has occurred in 28% and 44% of patients taking 120mg and 240mg faldaprevir regimens, respectively. Additionally, fatigue has occurred in 32% (120mg) and 35% (240mg) of patients, diarrhea has occurred in 25% (120mg) and 28% (240mg) of patients, headache has occurred in 24% (120mg) and 25% (240mg) of patients, asthenia has occurred in 26% (120mg) and 21% (240mg) of patients, and decreased appetite has occurred in 24% (120mg) and 20% (240mg) of patients. Thus far, discontinuation of faldaprevir due to AEs leading to the discontinuation of faldaprevir has occurred in 1% (120mg and 240mg) of patients. Serious AEs occurred in 14% (120mg) and 8% (240mg) of patients, resulting in one death from Stevens-Johnson syndrome (SJS) with onset 145 days after discontinuing treatment while on systemic antibiotics.

Additional Boehringer Ingelheim Data at the Meeting
Additional late breaking data from Boehringer Ingelheim's collaborative interferon-free trial with Presidio Pharmaceuticals will be presented on Monday, November 4. This ongoing Phase 2a study evaluates a 12-week, all-oral regimen of Boehringer Ingelheim's investigational compounds, faldaprevir and deleobuvir, in combination with Presidio's investigational pan-genotypic NS5
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014  To help health care ... that could impact patient care and the bottom ... Watch , "Innovations in Cardiovascular Devices."  ... guidance and details on promising new technologies that ... understand how these options impact the supply chain.   ...
(Date:7/24/2014)... 2014 Valeant Pharmaceuticals International, Inc. ("Valeant") ... that it has filed a detailed complaint with ... Inc.,s (NYSE: AGN ) apparent attempts ... market price of Valeant,s common shares by continuing ... business despite Valeant,s public statements correcting this misinformation. ...
(Date:7/24/2014)... 24, 2014 , Revenues from continuing ... , Adjusted diluted EPS from continuing operations of $1.08, up ... continuing operations of $0.92, 7% below prior year , ... year , Full year 2014 revenues now expected to ... previously , Full year 2014 adjusted diluted EPS range ...
Breaking Medicine Technology:New Novation CV Watch Shows Recent Technology Innovations Could Drive Cardiovascular Product Costs Up by as Much as 35 Percent 2New Novation CV Watch Shows Recent Technology Innovations Could Drive Cardiovascular Product Costs Up by as Much as 35 Percent 3Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 2Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 3Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 4Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 5Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 6Quest Diagnostics Reports Second Quarter 2014 Financial Results 2Quest Diagnostics Reports Second Quarter 2014 Financial Results 3Quest Diagnostics Reports Second Quarter 2014 Financial Results 4Quest Diagnostics Reports Second Quarter 2014 Financial Results 5Quest Diagnostics Reports Second Quarter 2014 Financial Results 6Quest Diagnostics Reports Second Quarter 2014 Financial Results 7Quest Diagnostics Reports Second Quarter 2014 Financial Results 8Quest Diagnostics Reports Second Quarter 2014 Financial Results 9Quest Diagnostics Reports Second Quarter 2014 Financial Results 10Quest Diagnostics Reports Second Quarter 2014 Financial Results 11Quest Diagnostics Reports Second Quarter 2014 Financial Results 12Quest Diagnostics Reports Second Quarter 2014 Financial Results 13Quest Diagnostics Reports Second Quarter 2014 Financial Results 14Quest Diagnostics Reports Second Quarter 2014 Financial Results 15Quest Diagnostics Reports Second Quarter 2014 Financial Results 16Quest Diagnostics Reports Second Quarter 2014 Financial Results 17Quest Diagnostics Reports Second Quarter 2014 Financial Results 18Quest Diagnostics Reports Second Quarter 2014 Financial Results 19Quest Diagnostics Reports Second Quarter 2014 Financial Results 20Quest Diagnostics Reports Second Quarter 2014 Financial Results 21Quest Diagnostics Reports Second Quarter 2014 Financial Results 22
... Bacterin International Holdings, Inc. (NYSE Amex: ... bone graft material and antimicrobial coatings for medical applications, reported ... Financial Highlights: Q2 2011 vs. Q2 2010 ... seventh consecutive quarter of record revenues. Net loss improved ...
... BEACH, Calif., Aug. 11, 2011 Diversified Medical Equipment ... medical supply company servicing the long-term care and home care ... medical supply store has more than doubled in size ... the company,s portfolio, www.dmes.com has grown to become ...
Cached Medicine Technology:Bacterin Second Quarter 2011 Revenues up 135% Over Prior Year, Driving First Positive EBITDA Quarter 2Bacterin Second Quarter 2011 Revenues up 135% Over Prior Year, Driving First Positive EBITDA Quarter 3Bacterin Second Quarter 2011 Revenues up 135% Over Prior Year, Driving First Positive EBITDA Quarter 4Bacterin Second Quarter 2011 Revenues up 135% Over Prior Year, Driving First Positive EBITDA Quarter 5Bacterin Second Quarter 2011 Revenues up 135% Over Prior Year, Driving First Positive EBITDA Quarter 6Bacterin Second Quarter 2011 Revenues up 135% Over Prior Year, Driving First Positive EBITDA Quarter 7Bacterin Second Quarter 2011 Revenues up 135% Over Prior Year, Driving First Positive EBITDA Quarter 8Bacterin Second Quarter 2011 Revenues up 135% Over Prior Year, Driving First Positive EBITDA Quarter 9DMES, Inc. Announces 100 Percent Growth for Online Medical Supply Store 2
(Date:7/24/2014)... with high-throughput data generated by breast cancer biologists ... computational method to determine how gene networks are ... as they respond to potential cancer therapy agents., ... each other in laboratory-grown cells is described in ... PLOS Computational Biology . , The method ...
(Date:7/24/2014)... who received the Human Papillomavirus Vaccination (HPV) even ... abnormal Pap test results than those who were ... Sexually Transmitted Diseases . , Researchers ... School of Medicine conducted a cross-sectional study of ... cervical cytology testing. HPV status and demographic and ...
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 ... Optometric Association (AOA) and the Entertainment Industries Council ... the TV series American Horror Story on a ... bring the dramatic realities of illegal and unsafe ... campaign, which has already reached tens-of-thousands, is now ...
(Date:7/24/2014)... Annual National Venous Interventional Summit is available at: ... established Venous Endovascular Interventional Strategies group comprised of ... to provide a "How To" meeting for cardiologists ... advancing their knowledge and skills in venous interventions ... comprehensive venous interventional program. Topics at this year,s ...
(Date:7/24/2014)... the strategy adopted by tumor cells to transform into ... a gloomy prognosis. Managing to block the metastasis or, ... step towards the fight against cancer. Researchers at Universit ... on models of human tumors in mice. The ... July in the prestigious journal Cell Reports . ...
Breaking Medicine News(10 mins):Health News:Gene changes in breast cancer cells pinpointed with new computational method 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 3Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 2Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 3Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 4Health News:Preliminary agenda available for 4th VEINS Conference to be held October 9-12 in Chicago 2Health News:A world first: Researchers identify a treatment that prevents tumor metastasis 2
... June 17 ANSi Consulting (ANSi) proudly announces its ... South Jersey,s 25 fastest-growing private companies in the eight-county ... on June 11th, held at The Merion in Cinnaminson, ... (ANSi,s very first company award) on behalf of all ...
... 15 Years of Healthcare Experience to Growing North Texas Company ... Faro joins Dallas-based North American Spine ... years of healthcare experience, specializing in the development, growth and ... role, Faro will lead North American Spine,s efforts to build ...
... announced today that it has received approval from the U.S. ... Filled Capsules, a new treatment option indicated for relief of ... age or older). , , "Zipsor is a drug ... Officer of Xanodyne. "It is the first NSAID to ...
... Applied Medical, a new generation medical company, was ... healthcare alliance ,s first Innovation Celebration, an annual ... industry suppliers committed to innovation and improving patient outcomes. ... that bring a positive impact to healthcare delivery. The ...
... revealed that despite the drooping economy Scots men are opting ... moob removal surgery and finally getting their insecurities off their ... Cosmetic Surgery Group has revealed that despite the drooping economy ... by booking in for moob removal surgery and finally getting ...
... Surgical Company (Nasdaq: STAA ), a leading ... today announced the approval of the KS-Ni Preloaded Silicone ... , , The KS-Ni Preloaded Silicone IOL Injector ... silicone IOL through an incision size of 2.6 mm ...
Cached Medicine News:Health News:ANSi Answers When Awarded the Philadelphia Business Journal's Prestigious 2009 South Jersey 25 Accolade 2Health News:Stephen D. Faro Joins North American Spine as Chief Operating Officer 2Health News:Stephen D. Faro Joins North American Spine as Chief Operating Officer 3Health News:Xanodyne Receives Approval From the U.S. Food and Drug Administration for ZIPSOR(TM) (diclofenac potassium) Liquid Filled Capsules 2Health News:Applied Medical Selected by the Premier Healthcare Alliance to Highlight Commitment to Healthcare Quality Improvement, Innovation 2Health News:Applied Medical Selected by the Premier Healthcare Alliance to Highlight Commitment to Healthcare Quality Improvement, Innovation 3Health News:Scots Men Get the Issue of Moobs Off Their Chests in Time for Summer - Male Surgery in Scotland Sees 80 Per Cent Growth 2Health News:Scots Men Get the Issue of Moobs Off Their Chests in Time for Summer - Male Surgery in Scotland Sees 80 Per Cent Growth 3Health News:STAAR Surgical Receives Japanese Clearance for the KS-Ni Preloaded IOL Injector System 2Health News:STAAR Surgical Receives Japanese Clearance for the KS-Ni Preloaded IOL Injector System 3
The Surgiflex WAVE XP couples the state-of-the-art Surgiflex WAVE Probe with the convenience of a truly portable battery-powered pump....
Stryker Endoscopy has combined a standardized pressurizing system with an advanced hand piece design that is lightweight and compact in order to streamline laparoscopic procedures....
... specifically to disintegrate renal and ... state-of-the-art technology in a compact ... efficient and affordable lithotripsy system. ... level of clinical results for ...
...
Medicine Products: